Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Tislelizumab vs Tislelizumab in 1L PD-L1+ Advanced NSCLC
CTR20222146Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Sep 2022; status: completed.
02
Drugs
tucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222146.